Monthly pulse methylprednisolone infusions in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases: a single-center retrospective analyses
PMP may offer a safer, better-tolerated, and more effective treatment for progressive non-IPF ILD than prolonged OCS. Notably, a third of fibrotic hypersensitivity pneumonitis patients showed improved FVC after 3 months of PMP, defying expectations of steroid non-responsiveness. However, further well-designed controlled prospective clinical trials are needed to confirm our findings and establish long-term safety.
Authors
- Fatima Dollar (ORCID: https://orcid.org/0000-0002-0620-8393)
- Jay I. Peters (ORCID: https://orcid.org/0000-0002-5230-1062)
- Jesse Sherratt
- Anoop M. Nambiar (ORCID: https://orcid.org/0000-0003-2778-0433)
- Sebastian Ocrospoma Heraud
- Dean L. Kellogg (ORCID: https://orcid.org/0000-0002-6550-3296)
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- South Texas Veterans Health Care System (US)
- The University of Texas at San Antonio (US)
Publication Details
- Journal
- Therapeutic Advances in Respiratory Disease
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17534666251342661
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00